Analysts forecast that Eagle Pharmaceuticals Inc (NASDAQ:EGRX) will announce $58.60 million in sales for the current quarter, according to Zacks. Two analysts have provided estimates for Eagle Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $57.30 million and the highest estimate coming in at $59.90 million. Eagle Pharmaceuticals reported sales of $63.02 million during the same quarter last year, which indicates a negative year over year growth rate of 7%. The firm is expected to report its next earnings results on Wednesday, November 14th.

On average, analysts expect that Eagle Pharmaceuticals will report full-year sales of $227.00 million for the current financial year, with estimates ranging from $225.90 million to $228.10 million. For the next financial year, analysts forecast that the business will report sales of $259.80 million per share, with estimates ranging from $243.90 million to $275.70 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that cover Eagle Pharmaceuticals.

Eagle Pharmaceuticals (NASDAQ:EGRX) last posted its quarterly earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported $0.95 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.80 by $0.15. Eagle Pharmaceuticals had a return on equity of 19.71% and a net margin of 13.81%. The business had revenue of $59.30 million for the quarter, compared to analyst estimates of $51.78 million.

Several research firms recently issued reports on EGRX. Cantor Fitzgerald set a $81.00 price target on Eagle Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, August 24th. TheStreet upgraded Eagle Pharmaceuticals from a “c” rating to a “b-” rating in a research report on Thursday, August 9th. Royal Bank of Canada set a $84.00 price target on Eagle Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 8th. Piper Jaffray Companies set a $88.00 price target on Eagle Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, August 7th. Finally, BidaskClub lowered Eagle Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 25th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $86.67.

EGRX traded down $2.18 on Thursday, hitting $66.95. 10,445 shares of the company were exchanged, compared to its average volume of 227,321. The company has a debt-to-equity ratio of 0.22, a current ratio of 4.22 and a quick ratio of 4.09. Eagle Pharmaceuticals has a 12 month low of $48.84 and a 12 month high of $85.66. The firm has a market cap of $1.04 billion, a price-to-earnings ratio of 19.53 and a beta of 1.33.

Hedge funds have recently modified their holdings of the company. New York State Common Retirement Fund grew its position in shares of Eagle Pharmaceuticals by 3.6% in the 1st quarter. New York State Common Retirement Fund now owns 64,467 shares of the specialty pharmaceutical company’s stock worth $3,397,000 after buying an additional 2,234 shares during the last quarter. Campbell Newman Asset Management Inc. grew its position in shares of Eagle Pharmaceuticals by 97.5% in the 2nd quarter. Campbell Newman Asset Management Inc. now owns 7,808 shares of the specialty pharmaceutical company’s stock worth $591,000 after buying an additional 3,854 shares during the last quarter. UBS Group AG grew its position in shares of Eagle Pharmaceuticals by 362.1% in the 1st quarter. UBS Group AG now owns 47,980 shares of the specialty pharmaceutical company’s stock worth $2,528,000 after buying an additional 37,597 shares during the last quarter. Chartwell Investment Partners LLC bought a new stake in shares of Eagle Pharmaceuticals in the 2nd quarter worth approximately $12,063,000. Finally, Citigroup Inc. grew its position in shares of Eagle Pharmaceuticals by 4.0% in the 1st quarter. Citigroup Inc. now owns 46,833 shares of the specialty pharmaceutical company’s stock worth $2,468,000 after buying an additional 1,806 shares during the last quarter.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL).

Featured Story: Dividend Stocks – Are They Right For You?

Get a free copy of the Zacks research report on Eagle Pharmaceuticals (EGRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.